SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : ARIAD Pharmaceuticals
ARIA 23.990.0%Feb 17 4:00 PM EST
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: Czechsinthemail who wrote (147)8/13/1997 10:48:00 PM
From: scaram(o)uche   of 4474
 
Lehman reiterated (8/6) it's 1-buy rating and $16 target on TXB after the SmithKline agreement for Novastan. I saw that the agreement didn't give TXB co-marketing unless they hit on indications beyond HIT, and I bailed on the morning of the announcement for 100% plus in a year (unfortunately, we're talking peanuts when we talk actual bucks).

One week later, Lehman is an underwriter on a 5 million share offering, and TXB is at 5, off about 25% from the day of the announcement.

Cool, huh?

Rick
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News